Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a prototype tumor wherein angiogenesis plays a vital role in its progression. The role of VEGF, a major angiogenic factor in HCC is known; however, the role of anti-angiogenic factors simultaneously with the angiogenic factors has not been studied before. Hence, in...
Gespeichert in:
| Veröffentlicht in: | Molecular and cellular biochemistry 2013-11, Vol.383 (1-2), p.103-112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 103 |
| container_title | Molecular and cellular biochemistry |
| container_volume | 383 |
| creator | Sharma, Bal Krishan Srinivasan, Radhika Kapil, Shweta Singla, Bhupesh Saini, Nitin Chawla, Yogesh Kumar Chakraborti, Anuradha Duseja, Ajay Kalra, Naveen Dhiman, Radha Krishan |
| description | Hepatocellular carcinoma (HCC) is a prototype tumor wherein angiogenesis plays a vital role in its progression. The role of VEGF, a major angiogenic factor in HCC is known; however, the role of anti-angiogenic factors simultaneously with the angiogenic factors has not been studied before. Hence, in this study, the serum levels of major angiogenic [Vascular Endothelial Growth Factor (VEGF), angiopoietin-2 (Ang-2)] and anti-angiogenic (endostatin, angiostatin) factors were analyzed and correlated with clinico-radiological features and with outcome. A total of 150 patients (50 HCC, 50 cirrhosis and 50 chronic hepatitis) and 50 healthy controls were enrolled in this study. Serum levels of VEGF, Ang-2, endostatin, and angiostatin were estimated by enzyme-linked immunosorbent assay. HCC shows significantly elevated serum levels of angiogenic factors VEGF and Ang-2 and of anti-angiogenic factors endostatin and angiostatin. ROC curve analysis for serum VEGF yielded an optimal cut-off value of 225.14 pg/ml, with a sensitivity of 78 % and specificity of 84.7 % for a diagnosis of HCC and its distinction from other group. Using this value, the univariate and multivariate analysis revealed significantly poor outcome in patients with higher levels of serum VEGF (
p
= 0.009). Combinatorial analysis revealed that patients with higher levels of both angiogenic and anti-angiogenic factors showed poor outcome. Serum VEGF correlates with poor survival of HCC patients and, therefore, serves as a non-invasive biomarker of poor prognosis. Moreover, elevated levels of anti-angiogenic factors occur endogenously in HCC patients. |
| doi_str_mv | 10.1007/s11010-013-1759-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443399301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A350791585</galeid><sourcerecordid>A350791585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-dcc5c9706dda1751a9c7dec3b93de291f215e7a96e8073b544d392b446ee84103</originalsourceid><addsrcrecordid>eNp1UcFu1DAQtRCIbhc-gAuyxIWLiydO4phbVQFFqsQBOFtee5K6cuzFTpB64tfxsgUKAlkjWzPvPb3xI-QZ8DPgXL4qABw44yAYyE4x-YBsoJOCtQrUQ7LhgnM2gJQn5LSUG17BHOAxOWmEglr9hnz7iHmdacCvGApNIzVx8mnC6G19ulqLZ_d6o7FLyuU1Xa7RZ7rPaYqpLHWSsYqYaJH6SEOyJoRbatyPlqPXuDdLshjCGkym1mTrY5rNE_JoNKHg07t7Sz6_ffPp4pJdfXj3_uL8itlWqIU5azurJO-dM3VVMMpKh1bslHDYKBgb6FAa1ePApdh1beuEanZt2yMOLXCxJS-PutXxlxXLomdfDnZMxLQWDW0rhFKi_uWWvPgLepPWHKu7ihKD6Ide8N-oyQTUPo5pycYeRPW56LhU0A1dRZ39A1WPw9nbFHH0tf8HAY4Em1MpGUe9z342-VYD14fQ9TF0XY3qQ-haVs7zO8Prbkb3i_Ez5QpojoBSR3HCfG-j_6p-B-1HtxI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1438368630</pqid></control><display><type>article</type><title>Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sharma, Bal Krishan ; Srinivasan, Radhika ; Kapil, Shweta ; Singla, Bhupesh ; Saini, Nitin ; Chawla, Yogesh Kumar ; Chakraborti, Anuradha ; Duseja, Ajay ; Kalra, Naveen ; Dhiman, Radha Krishan</creator><creatorcontrib>Sharma, Bal Krishan ; Srinivasan, Radhika ; Kapil, Shweta ; Singla, Bhupesh ; Saini, Nitin ; Chawla, Yogesh Kumar ; Chakraborti, Anuradha ; Duseja, Ajay ; Kalra, Naveen ; Dhiman, Radha Krishan</creatorcontrib><description>Hepatocellular carcinoma (HCC) is a prototype tumor wherein angiogenesis plays a vital role in its progression. The role of VEGF, a major angiogenic factor in HCC is known; however, the role of anti-angiogenic factors simultaneously with the angiogenic factors has not been studied before. Hence, in this study, the serum levels of major angiogenic [Vascular Endothelial Growth Factor (VEGF), angiopoietin-2 (Ang-2)] and anti-angiogenic (endostatin, angiostatin) factors were analyzed and correlated with clinico-radiological features and with outcome. A total of 150 patients (50 HCC, 50 cirrhosis and 50 chronic hepatitis) and 50 healthy controls were enrolled in this study. Serum levels of VEGF, Ang-2, endostatin, and angiostatin were estimated by enzyme-linked immunosorbent assay. HCC shows significantly elevated serum levels of angiogenic factors VEGF and Ang-2 and of anti-angiogenic factors endostatin and angiostatin. ROC curve analysis for serum VEGF yielded an optimal cut-off value of 225.14 pg/ml, with a sensitivity of 78 % and specificity of 84.7 % for a diagnosis of HCC and its distinction from other group. Using this value, the univariate and multivariate analysis revealed significantly poor outcome in patients with higher levels of serum VEGF (
p
= 0.009). Combinatorial analysis revealed that patients with higher levels of both angiogenic and anti-angiogenic factors showed poor outcome. Serum VEGF correlates with poor survival of HCC patients and, therefore, serves as a non-invasive biomarker of poor prognosis. Moreover, elevated levels of anti-angiogenic factors occur endogenously in HCC patients.</description><identifier>ISSN: 0300-8177</identifier><identifier>EISSN: 1573-4919</identifier><identifier>DOI: 10.1007/s11010-013-1759-7</identifier><identifier>PMID: 23912396</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Angiogenesis ; Angiogenesis Inducing Agents - blood ; Angiogenesis Inhibitors - blood ; Angiostatins - blood ; Antimitotic agents ; Antineoplastic agents ; Biochemistry ; Biomarkers ; Biomedical and Life Sciences ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - pathology ; Cardiology ; Endostatins - blood ; Hepatitis ; Hepatoma ; Humans ; Kaplan-Meier Estimate ; Life Sciences ; Liver cancer ; Liver cirrhosis ; Liver Neoplasms - blood ; Liver Neoplasms - pathology ; Medical Biochemistry ; Multivariate Analysis ; Neoplasm Staging ; Oncology ; Prognosis ; Proportional Hazards Models ; ROC Curve ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - blood ; Vesicular Transport Proteins - blood</subject><ispartof>Molecular and cellular biochemistry, 2013-11, Vol.383 (1-2), p.103-112</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>COPYRIGHT 2013 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-dcc5c9706dda1751a9c7dec3b93de291f215e7a96e8073b544d392b446ee84103</citedby><cites>FETCH-LOGICAL-c439t-dcc5c9706dda1751a9c7dec3b93de291f215e7a96e8073b544d392b446ee84103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11010-013-1759-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11010-013-1759-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23912396$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Bal Krishan</creatorcontrib><creatorcontrib>Srinivasan, Radhika</creatorcontrib><creatorcontrib>Kapil, Shweta</creatorcontrib><creatorcontrib>Singla, Bhupesh</creatorcontrib><creatorcontrib>Saini, Nitin</creatorcontrib><creatorcontrib>Chawla, Yogesh Kumar</creatorcontrib><creatorcontrib>Chakraborti, Anuradha</creatorcontrib><creatorcontrib>Duseja, Ajay</creatorcontrib><creatorcontrib>Kalra, Naveen</creatorcontrib><creatorcontrib>Dhiman, Radha Krishan</creatorcontrib><title>Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma</title><title>Molecular and cellular biochemistry</title><addtitle>Mol Cell Biochem</addtitle><addtitle>Mol Cell Biochem</addtitle><description>Hepatocellular carcinoma (HCC) is a prototype tumor wherein angiogenesis plays a vital role in its progression. The role of VEGF, a major angiogenic factor in HCC is known; however, the role of anti-angiogenic factors simultaneously with the angiogenic factors has not been studied before. Hence, in this study, the serum levels of major angiogenic [Vascular Endothelial Growth Factor (VEGF), angiopoietin-2 (Ang-2)] and anti-angiogenic (endostatin, angiostatin) factors were analyzed and correlated with clinico-radiological features and with outcome. A total of 150 patients (50 HCC, 50 cirrhosis and 50 chronic hepatitis) and 50 healthy controls were enrolled in this study. Serum levels of VEGF, Ang-2, endostatin, and angiostatin were estimated by enzyme-linked immunosorbent assay. HCC shows significantly elevated serum levels of angiogenic factors VEGF and Ang-2 and of anti-angiogenic factors endostatin and angiostatin. ROC curve analysis for serum VEGF yielded an optimal cut-off value of 225.14 pg/ml, with a sensitivity of 78 % and specificity of 84.7 % for a diagnosis of HCC and its distinction from other group. Using this value, the univariate and multivariate analysis revealed significantly poor outcome in patients with higher levels of serum VEGF (
p
= 0.009). Combinatorial analysis revealed that patients with higher levels of both angiogenic and anti-angiogenic factors showed poor outcome. Serum VEGF correlates with poor survival of HCC patients and, therefore, serves as a non-invasive biomarker of poor prognosis. Moreover, elevated levels of anti-angiogenic factors occur endogenously in HCC patients.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inducing Agents - blood</subject><subject>Angiogenesis Inhibitors - blood</subject><subject>Angiostatins - blood</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Biochemistry</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cardiology</subject><subject>Endostatins - blood</subject><subject>Hepatitis</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - pathology</subject><subject>Medical Biochemistry</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>ROC Curve</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>Vesicular Transport Proteins - blood</subject><issn>0300-8177</issn><issn>1573-4919</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1UcFu1DAQtRCIbhc-gAuyxIWLiydO4phbVQFFqsQBOFtee5K6cuzFTpB64tfxsgUKAlkjWzPvPb3xI-QZ8DPgXL4qABw44yAYyE4x-YBsoJOCtQrUQ7LhgnM2gJQn5LSUG17BHOAxOWmEglr9hnz7iHmdacCvGApNIzVx8mnC6G19ulqLZ_d6o7FLyuU1Xa7RZ7rPaYqpLHWSsYqYaJH6SEOyJoRbatyPlqPXuDdLshjCGkym1mTrY5rNE_JoNKHg07t7Sz6_ffPp4pJdfXj3_uL8itlWqIU5azurJO-dM3VVMMpKh1bslHDYKBgb6FAa1ePApdh1beuEanZt2yMOLXCxJS-PutXxlxXLomdfDnZMxLQWDW0rhFKi_uWWvPgLepPWHKu7ihKD6Ide8N-oyQTUPo5pycYeRPW56LhU0A1dRZ39A1WPw9nbFHH0tf8HAY4Em1MpGUe9z342-VYD14fQ9TF0XY3qQ-haVs7zO8Prbkb3i_Ez5QpojoBSR3HCfG-j_6p-B-1HtxI</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Sharma, Bal Krishan</creator><creator>Srinivasan, Radhika</creator><creator>Kapil, Shweta</creator><creator>Singla, Bhupesh</creator><creator>Saini, Nitin</creator><creator>Chawla, Yogesh Kumar</creator><creator>Chakraborti, Anuradha</creator><creator>Duseja, Ajay</creator><creator>Kalra, Naveen</creator><creator>Dhiman, Radha Krishan</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma</title><author>Sharma, Bal Krishan ; Srinivasan, Radhika ; Kapil, Shweta ; Singla, Bhupesh ; Saini, Nitin ; Chawla, Yogesh Kumar ; Chakraborti, Anuradha ; Duseja, Ajay ; Kalra, Naveen ; Dhiman, Radha Krishan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-dcc5c9706dda1751a9c7dec3b93de291f215e7a96e8073b544d392b446ee84103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inducing Agents - blood</topic><topic>Angiogenesis Inhibitors - blood</topic><topic>Angiostatins - blood</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Biochemistry</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cardiology</topic><topic>Endostatins - blood</topic><topic>Hepatitis</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - pathology</topic><topic>Medical Biochemistry</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>ROC Curve</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>Vesicular Transport Proteins - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Bal Krishan</creatorcontrib><creatorcontrib>Srinivasan, Radhika</creatorcontrib><creatorcontrib>Kapil, Shweta</creatorcontrib><creatorcontrib>Singla, Bhupesh</creatorcontrib><creatorcontrib>Saini, Nitin</creatorcontrib><creatorcontrib>Chawla, Yogesh Kumar</creatorcontrib><creatorcontrib>Chakraborti, Anuradha</creatorcontrib><creatorcontrib>Duseja, Ajay</creatorcontrib><creatorcontrib>Kalra, Naveen</creatorcontrib><creatorcontrib>Dhiman, Radha Krishan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular and cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Bal Krishan</au><au>Srinivasan, Radhika</au><au>Kapil, Shweta</au><au>Singla, Bhupesh</au><au>Saini, Nitin</au><au>Chawla, Yogesh Kumar</au><au>Chakraborti, Anuradha</au><au>Duseja, Ajay</au><au>Kalra, Naveen</au><au>Dhiman, Radha Krishan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma</atitle><jtitle>Molecular and cellular biochemistry</jtitle><stitle>Mol Cell Biochem</stitle><addtitle>Mol Cell Biochem</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>383</volume><issue>1-2</issue><spage>103</spage><epage>112</epage><pages>103-112</pages><issn>0300-8177</issn><eissn>1573-4919</eissn><abstract>Hepatocellular carcinoma (HCC) is a prototype tumor wherein angiogenesis plays a vital role in its progression. The role of VEGF, a major angiogenic factor in HCC is known; however, the role of anti-angiogenic factors simultaneously with the angiogenic factors has not been studied before. Hence, in this study, the serum levels of major angiogenic [Vascular Endothelial Growth Factor (VEGF), angiopoietin-2 (Ang-2)] and anti-angiogenic (endostatin, angiostatin) factors were analyzed and correlated with clinico-radiological features and with outcome. A total of 150 patients (50 HCC, 50 cirrhosis and 50 chronic hepatitis) and 50 healthy controls were enrolled in this study. Serum levels of VEGF, Ang-2, endostatin, and angiostatin were estimated by enzyme-linked immunosorbent assay. HCC shows significantly elevated serum levels of angiogenic factors VEGF and Ang-2 and of anti-angiogenic factors endostatin and angiostatin. ROC curve analysis for serum VEGF yielded an optimal cut-off value of 225.14 pg/ml, with a sensitivity of 78 % and specificity of 84.7 % for a diagnosis of HCC and its distinction from other group. Using this value, the univariate and multivariate analysis revealed significantly poor outcome in patients with higher levels of serum VEGF (
p
= 0.009). Combinatorial analysis revealed that patients with higher levels of both angiogenic and anti-angiogenic factors showed poor outcome. Serum VEGF correlates with poor survival of HCC patients and, therefore, serves as a non-invasive biomarker of poor prognosis. Moreover, elevated levels of anti-angiogenic factors occur endogenously in HCC patients.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23912396</pmid><doi>10.1007/s11010-013-1759-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8177 |
| ispartof | Molecular and cellular biochemistry, 2013-11, Vol.383 (1-2), p.103-112 |
| issn | 0300-8177 1573-4919 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1443399301 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Angiogenesis Angiogenesis Inducing Agents - blood Angiogenesis Inhibitors - blood Angiostatins - blood Antimitotic agents Antineoplastic agents Biochemistry Biomarkers Biomedical and Life Sciences Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - pathology Cardiology Endostatins - blood Hepatitis Hepatoma Humans Kaplan-Meier Estimate Life Sciences Liver cancer Liver cirrhosis Liver Neoplasms - blood Liver Neoplasms - pathology Medical Biochemistry Multivariate Analysis Neoplasm Staging Oncology Prognosis Proportional Hazards Models ROC Curve Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood Vesicular Transport Proteins - blood |
| title | Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A50%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20angiogenic%20and%20anti-angiogenic%20factors:%20their%20prognostic%20relevance%20in%20locally%20advanced%20hepatocellular%20carcinoma&rft.jtitle=Molecular%20and%20cellular%20biochemistry&rft.au=Sharma,%20Bal%20Krishan&rft.date=2013-11-01&rft.volume=383&rft.issue=1-2&rft.spage=103&rft.epage=112&rft.pages=103-112&rft.issn=0300-8177&rft.eissn=1573-4919&rft_id=info:doi/10.1007/s11010-013-1759-7&rft_dat=%3Cgale_proqu%3EA350791585%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1438368630&rft_id=info:pmid/23912396&rft_galeid=A350791585&rfr_iscdi=true |